Ma H - Search Results

1

The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China.

Yang J, Zhao L, Wu Y, Niu T, Gong Y, Chen X, Huang X, Liu J, Dai Y, Ma H. Yang J, et al. Among authors: ma h. Cancer Med. 2023 Dec;12(23):21111-21117. doi: 10.1002/cam4.6669. Epub 2023 Nov 8. Cancer Med. 2023. PMID: 37937729 Free PMC article.

2

[Studies on the predictors of response to immunosuppressive therapy in severe aplastic anemia patients].

Mu XY, Chang H, Liu T, Gong YP, Niu T, Qin H, Ma HB, Meng WT. Mu XY, et al. Among authors: ma hb. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Sep;40(5):897-900. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009. PMID: 19950609 Chinese.

3

Antileukaemia effect of rapamycin alone or in combination with daunorubicin on Ph+ acute lymphoblastic leukaemia cell line.

Yang X, Lin J, Gong Y, Ma H, Shuai X, Zhou R, Guo Y, Shan Q, He G. Yang X, et al. Among authors: ma h. Hematol Oncol. 2012 Sep;30(3):123-30. doi: 10.1002/hon.1013. Epub 2011 Sep 4. Hematol Oncol. 2012. PMID: 21898527

4

Sustaining integrating imatinib and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation.

Kuang P, Liu T, Pan L, Zhu H, Wu Y, Ye Y, Xiang B, Ma H, Chang H, Niu T, Cui X, He C, Li J, Ji J, Huang J, Dong T, Dai Y, Lu X, Qing S, Wu H, Liang X, Wang X, Wu C. Kuang P, et al. Among authors: ma h. Leuk Lymphoma. 2016 Oct;57(10):2321-9. doi: 10.3109/10428194.2016.1144882. Epub 2016 Feb 16. Leuk Lymphoma. 2016. PMID: 26879808

5

Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.

Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M, Guan P, Zou X, Valencia CA, Dong B, Li J, Xie L, Ma H, Wang F, Dong T, Shuai X, Niu T, Liu T. Zhang L, et al. Among authors: ma h. Oncotarget. 2016 May 24;7(21):30876-91. doi: 10.18632/oncotarget.9021. Oncotarget. 2016. PMID: 27129167 Free PMC article.

6

Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.

Guo Y, Li Y, Xiang B, Huang XO, Ma HB, Wang FF, Gong YP. Guo Y, et al. Biochem J. 2017 Dec 6;474(24):4153-4170. doi: 10.1042/BCJ20170386. Biochem J. 2017. PMID: 29046392

7

The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.

Guo Y, Li Y, Wang FF, Xiang B, Huang XO, Ma HB, Gong YP. Guo Y, et al. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008. Epub 2018 Oct 30. Int J Biochem Cell Biol. 2019. PMID: 30389549

8

Adoptive cell therapy for acute myeloid leukemia.

Ma H, Padmanabhan Iyer S, Parmar S, Gong Y. Ma H, et al. Leuk Lymphoma. 2019 Jun;60(6):1370-1380. doi: 10.1080/10428194.2018.1553300. Epub 2019 Jan 10. Leuk Lymphoma. 2019. PMID: 30628504 Review.

9

Targeting CLL-1 for acute myeloid leukemia therapy.

Ma H, Padmanabhan IS, Parmar S, Gong Y. Ma H, et al. J Hematol Oncol. 2019 Apr 24;12(1):41. doi: 10.1186/s13045-019-0726-5. J Hematol Oncol. 2019. PMID: 31014360 Free PMC article. Review.

10

[Efficacy of Different Doses of Daunorubicin Induced Chemotherapy in Patients with Newly Diagnosed Primary Acute Myeloid Leukemia Under 65 Years Old].

Gong SG, Wang FJ, Wang ST, Zheng Q, Shuai X, Ma HB, Zhang L, Chen XC, Wu Y, Jia YQ. Gong SG, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1071-1079. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.009. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 34362484 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19,711 results

Search Page

Filters